-
Mashup Score: 0
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1In TROPION-Lung01, Dato-DXd Continues to Show Promise in NSCLC - 5 month(s) ago
The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Dato-DXd numerically improved OS vs docetaxel in patients with locally advanced or metastatic #NSCLC treated with at least 1 prior line of therapy, but the improvement was not statistically significant. #WCLC24 | @sands_jacob @DanaFarber https://t.co/jhOeKY112U
-
-
Mashup Score: 0
In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
“The highest pCR and mPR rates were seen with Dato-DXd plus durvalumab and single-agent platinum chemotherapy," said Tina Cascone, MD, PhD. #NSCLC #WCLC24 | @IASLC https://t.co/I4KmaJOlIb
-
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated #NSCLC. #WCLC24 @IASLC https://t.co/BpEE4XmqVD